JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on January 23, 2004; DOI: 10.1124/jpet.103.063396


0022-3565/04/3092-533-539$20.00
JPET 309:533-539, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.063396v1
309/2/533    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marcet, B.
Right arrow Articles by Verrier, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marcet, B.
Right arrow Articles by Verrier, B.

CELLULAR AND MOLECULAR

Pharmacological and Signaling Properties of Endogenous P2Y1 Receptors in Cystic Fibrosis Transmembrane Conductance Regulator-Expressing Chinese Hamster Ovary Cells

Brice Marcet, Valérie Chappe, Patrick Delmas, and Bernard Verrier

Institut de Neurosciences Physiologiques et Cognitives, Centre National de la Recherche Scientifique-INPC, Marseille, France (B.M., B.V.); McGill University, Department of Physiology, Montreal, Canada (V.C.); and Intégration des Informations Sensorielles, Centre National de la Recherche Scientifique-UMR 6150, Faculté de Médecine, l'Institut Fédératif de Recherche Jean Roche, Marseille, France (P.D.)

The cystic fibrosis (CF) transmembrane conductance regulator (CFTR) is a cAMP-dependent Cl- channel that is defective in CF disease. CFTR activity has been shown to be regulated by the Gq/phospholipase C-linked P2Y2 subtype of P2Y nucleotide receptors (P2YR) in various systems. Here, we tested whether other P2YR may exert a regulation on CFTR activity and whether CFTR may in turn exert a regulation on P2YR signaling. Using reverse transcriptase-polymerase chain reactions, antisense oligodeoxynucleotide knockdown, and measurements of intracellular calcium concentration ([Ca2+]i), we showed that, in addition to P2Y2R, Chinese hamster ovary (CHO) cells also express functional P2Y1R. P2Y1R were activated by 2-methylthioadenosine 5'-diphosphate > 2-methylthioadenosine-5'-triphosphate > ADP with an EC50 of 30 nM, 0.2 µM, and 0.8 µM, respectively. Activation of P2Y1R increased [Ca2+]i, which was prevented by the P2Y1R antagonists pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS) (10 µM) and N6-methyl 2'-deoxyadenosine 3',5'-bisphosphate (MRS2179) (10 µM) and by pretreatment with P2Y1R antisense oligodeoxynucleotides. In CHO-K1 and CHO-KNUT (mock-transfected) cells lacking CFTR, both P2Y1R and P2Y2R caused [Ca2+]i mobilization via pertussis toxin (PTX)-insensitive Gq/11-proteins. In contrast, in CFTR-expressing CHO cells (CHO-BQ1), the P2Y1R response was completely PTX-sensitive, indicating that P2Y1R couples to Gi/o-proteins, whereas the P2Y2R response remained PTX-insensitive. In CHO-BQ1 cells, P2Y1R activation by ADP (100 µM) failed to inhibit both forskolin (1 µM)-induced CFTR activation, measured using iodide (125I) efflux, and forskolin (0.1-10 µM)-evoked cAMP increase. Together, our results indicate that, in contrast to P2Y2R, P2Y1R does not modulate CFTR activity in CHO cells and that CFTR expression may alter the G-protein-coupling selectivity of P2Y1R.


Received November 21, 2003; accepted January 21, 2004.

Address correspondence to: Dr. Brice Marcet, INPC-CNRS, 31 Chemin Joseph Aiguier 13402 Marseille cedex 20, France. E-mail: marcet{at}dpm.cnrs-mrs.fr







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.